Antagonistic activity of selenium-enriched Bifidobacterium breve against Clostridioides difficile

Whole genome sequencing and analysis of selenite-reducing bacteria Bacillus paralicheniformis SR14 in response to different sugar supplements

“…Numerous theories existed regarding the process of bio-reduction of selenite to elemental selenium, which involved in multiple metabolic pathways (Wang et al 2022a , b ), including glutathione reductase-dependent reduction (Kessi and Hanselmann 2004 ), TrxR-dependent reduction (Rui et al 2022 ), siderophore or sulfide-mediated reduction (Zannoni et al 2008 ), and dissimilatory reduction (Song et al 2017 ). In this study, RT-PCR results indicated that multiple selenite-reducing enzymes were found to be significantly expressed only after glucose supplementation, including thioredoxin, fumarate reductase, and glutathione peroxidase.…”

“…TrxR is one of the most important selenoenzyme that would be mainly involved in the detoxification of selenite (Jia et al 2022 ). A recent study showed that selenium-enriched Bifidobacterium breve YH68-Se enhanced activities of TrxR and glutathione peroxidase with increasing selenite concentration (Rui et al 2022 ). Shimizu et al showed that selenite was reduced by the thioredoxin system from Pseudomonas stutzeri (Shimizu et al 2021 ), which was consistent with other studies on Alcaligenes faecalis (Wang et al 2018b ).…”

Strategies for applying probiotics in the antibiotic management ofClostridioides difficileinfection

“…147 Similarly, Roussel et al found that the consumption of ω-3 polyunsaturated fatty acids (ω-3 PUFAs) was also able to modulate the host gut microbiota structure by increasing A. muciniphila. 148 Trace 48 The combination of probiotics with other beneficial substances can enhance the viability of the strain while providing other health benefits, and such combinations may provide gains in the efficacy of the "bacteria-drug combination" model.…”

“…47 More probiotics that are effective at inhibiting CDI are still in the laboratory stage and need further clinical validation. 48–52 In our previous study, we identified a strain of Bifidobacterium breve that strongly antagonized C. difficile and demonstrated excellent therapeutic efficacy in a pCDI mouse model. 53,54 (2) In cases where probiotics are not effective, or are even ineffective, the subsequent intervention of antibiotics is required to achieve the desired efficacy.…”

“…149 For example, for Se-enriched B. breve prepared by Rui et al , this Se-enriched strain containing SeNPs significantly inhibited C. difficile growth, spore and biofilm production, toxin production, and expression of the tcdA / B virulence gene, and disrupted C. difficile cell membrane permeability and integrity in a short period, eventually causing bacterial death. 48 The combination of probiotics with other beneficial substances can enhance the viability of the strain while providing other health benefits, and such combinations may provide gains in the efficacy of the “bacteria–drug combination” model.…”